TheraRadar
← Back
Data updated: Jun 28, 2026

PURDUE PHARMA

Pharma
Immunology Execution: Fair

PURDUE PHARMA is a pharmaceutical company focused on Immunology. Key products include INTERMEZZO.

2008
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

PURDUE PHARMA at a Glance

  • Fast trial execution (13 months median completion)

PURDUE PHARMA's Key Drugs

PURDUE PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PURDUE PHARMA's Recent FDA Approvals

New NDA/BLA approvals for PURDUE PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PURDUE PHARMA's Therapeutic Areas

PURDUE PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
0 drugs Phase 2: 3

PURDUE PHARMA's Top Competitors

PURDUE PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Immunology
Novartis big-pharma
Immunology
AbbVie big-pharma
Immunology
Johnson & Johnson big-pharma
Immunology
GSK big-pharma
Immunology

PURDUE PHARMA Pipeline Snapshot

PURDUE PHARMA has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 3 Phase 2 and 0 Phase 1.

0
Phase 3
3
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 13 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges